“A Prospective Clinical Utility Study Demonstrates That Physicians Use the 40-Gene Expression Profile (40-GEP) to Guide Clinical Management Decisions for Medicare-Eligible Patients With Cutaneous Squamous Cell Carcinoma (cSCC)”. SKIN The Journal of Cutaneous Medicine 6, no. 6 (November 16, 2022): s95. Accessed May 25, 2026. https://skin.dermsquared.com/skin/article/view/1854.